US market for drug packaging worth $16bn by 2012

June 11, 2008

Advanced functionalities, including those that aid patient compliance, will come to dominate the drug packaging market over the next few years, according to a study by the Freedonia Group In April, the World Health Organization (WHO) said that poor treatment compliance costs the global drug industry around $30bn (€19.4bn) a year. The organization also suggested that “shifting the effectiveness of patient adherence may have a far greater impact on the health of the population than any improvement in medical treatment.”

Among those likely to welcome Freedonia‘s forecast will be US packaging specialist Alcan, which is involved in the development and manufacture of blister pack and wallet technologies that are designed to both encourage and remind patients of dosing regimens and to aid understanding of their disease.

Injectables and transdermals

Freedonia predicts that the US pharmaceutical packaging market will grow 5.5 per cent a year and be worth $16bn (€10.3bn) by 2012. The report expects that the demand for parenteral vials, dispensing bottles, pre-fillable inhalers and syringes, track and trace labels, unit dose pouches and other added-value containers will drive the expansion.

The group also predicted that the market for primary pharmaceutical containers such as pre-fillable syringes and vials will grow to a value of $9.6bn, driven by the production of new injectable biologic therapies.

The report goes on to predict that plastic bottles will remain the most widely used packaging system for oral medications, including both bulk and prescription drug products. Plastic bottles are also expected to maintain their dominance of the over-the-counter (OTC) market, particularly those for products that are sold in quantities of 50 capsules or more.

Source: Outsourcing Pharma